Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A new study has tested if a daily, 4-week intake of a multispecies probiotic improved emotional processing in people with untreated moderate depression.

Bacteria Bifidobacterium, part of normal flora of human intestine, used as probiotics and in yoghurt production.

Dietary supplementation with probiotics - live cultures of "good" bacteria - has been shown to influence brain function, but the understanding of the underlaying mechanisms involved in this remain elusive.

Associate Professor Phil Burnet, Department of Psychiatry, University of Oxford, said:

 

'Our study shows that taking a probiotic supplement alters emotional processing and improves mood in people with moderate depression. These data provide further evidence for gut bacteria affecting human brain function.

'Understanding the influence of probiotics on emotions may suggest how they should be most effectively combined with other interventions in the treatment of mental health conditions. People with moderate depression are often reluctant to seek medical help as they may be worried about taking medication. Our findings suggest that probiotics could be used as an early intervention to help reduce the risk of people with mild to moderate depression developing a major depressive disorder, which is more debilitating and often difficult to treat. However, it is important to note that probiotics will never, and should not, replace current pharmacological and psychological therapies.'

The study included 71 participants in a randomised double-blind, placebo-controlled trial. Results showed that the participants who took the probiotic had increased accuracy at identifying faces expressing all emotions and vigilance to neutral faces, this is different to the reported action of commonly used antidepressants, which reduce attention to negative emotions.

Associate Professor Burnet continues:

'Testing a larger population of people with other probiotics and narrowing down exactly which bacteria are influencing the processes in the periphery that lead to changes in the brain would be a helpful next step. This would then have the potential to lead to the development of new treatments for depression when conventional approaches may not be appropriate.'

Read the full paper, Multispecies probiotic administration reduces emotional salience and improves mood in subjects with moderate depression: a randomised, double-blind, placebo-controlled study.

NIHR OXFORD HEALTH BIOMEDICAL RESEARCH CENTRE NEWS

Please follow the link below to read the news on the NIHR BRC website.

Similar stories

‘Thinking Family’ when an adult has a serious illness

New research shows that although patient’s family details were often recorded, this information was not routinely used to help patients share their diagnosis with children.

Treating mental illness with electricity - new podcast

A new wave of treatments that stimulate the brain with electricity are showing promise on patients and in clinical trials.

Hours of gaming not negatively impacting wellbeing of most adolescents - new study

University of Oxford researchers found that although many school-age adolescents are spending considerable time gaming, it is not having a negative impact on their wellbeing.

Few mental health apps make it to real world, according to new Oxford University study

Despite enthusiasm for digital technology in addressing young people’s mental health, few effective apps have been successfully rolled out.

Oxford gets £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients.

Dementia research - new trial with diabetes drug

An important new trial will test the effects of oral semaglutide on the build-up of a protein in the brain that characterises Alzheimer's disease.